All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-06-04T15:54:28.000Z

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?

By Cynthia Umukoro
Featured
Eunice Wang
Jun 4, 2018
Share:

Bookmark this article

 At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Eunice S. Wang from Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks about novel agents including ivosidenib, an oral targeted inhibitor of mutant IDH1, and venetoclax, a BCL-2 inhibitor which have both demonstrated promising results in patients with acute myeloid leukemia (AML).

 

What are the new advances in AML treatment?

More about...
AML-related mutationsASCO 2018EnasidenibIDH1IvosidenibVenetoclax

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
28 votes - 49 days left ...

Related articles

Add bookmark

August 2019 | Druggable mutations in AML

This month's educational theme in acute myeloid leukemia surrounds druggable muations. Here, we summarise our past content on this theme.

Aug 7, 2019
Add bookmark

August 2019 | Druggable mutations in AML

This month's educational theme in acute myeloid leukemia surrounds druggable muations. Here, we summarise our past content on this theme.

Aug 7, 2019
Add bookmark

Uma Borate | ASCO 2018 | Impact of targeted therapy on treatment of AML

Uma Borate discusses new targeted therapies for acute myeloid leukemia (AML) including venetoclax in combination with azacitidine, ivosidenib, and enasidenib. 

Jun 4, 2018
Add bookmark

Uma Borate | ASCO 2018 | Impact of targeted therapy on treatment of AML

Uma Borate discusses new targeted therapies for acute myeloid leukemia (AML) including venetoclax in combination with...

Jun 4, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox